Pharmacogenetics
Appendix 3: Methods of working
In December 2001, the Council held a Workshop that addressed issues arising from developments in pharmacogenetics. Subsequently, in September 2002, the Working Party on Pharmacogenetics was established. The Working Party met six times between September 2002 and June 2003. As part of its work, the Working Party held five fact-finding sessions with experts in a number of fields. The Working Party also held a consultation with the public, the responses to which are summarised in Appendix 4.
Mr Jai Shah prepared background research for the Working Party while working as an intern at the Nuffield Council on Bioethics between 8 July 2002 and 12 September 2002. This research formed part of his MSc in International Health Policy at the London School of Economics. Fact-finding meetings
The Working Party is very grateful to the following individuals for taking the time to meet with members of the Working Party and for providing insights into issues relating to pharmacogenetics.1
25 November 2002, London
Professor David Goldstein
Wolfson Professor of Genetics, University College London
Dr Rashmi Shah
Senior Clinical Assessor, Medicines Control Agency
Mr Adrian Towse
Director, Office of Health Economics
25 February 2003, London
Professor Alastair Bellingham CBE
Chief Executive, NHS Information Authority
Mr Cliff Prior
Chief Executive, Rethink (formerly the National Schizophrenia Fellowship)
Dr Virginia Warren
Assistant Medical Director, BUPA
25 February 2003, London
Dr Kevin Cheeseman
Director of Development Pharmacogenetics, AstraZeneca
Mr Andrew Freeman
RADEX Operations and Policy, GlaxoSmithKline
Dr Duncan McHale
Clinical Pharmacogenetics, Pfizer
Dr Philip Wright
Director, Association of the British Pharmaceutical Industry
13 March 2003, London
Professor Jonathan Montgomery
Professor of Health Care Law, University of Southampton
Mr John Wilkinson
Partner and Joint Head of the Life Sciences Group, Bird and Bird
20 March 2003, London
Mr Ian Dodds-Smith
Partner, Co-Head of Food, Drug and Medical Devices Practice Group and Head of European
Product Liability Practice Group, Arnold and Porter
Dr Kathleen Fadden
Senior Associate, Arnold and Porter
1 Institutional affiliations at the time of the meeting are listed.